APOE and metabolic dysfunction-associated steatotic liver disease: Altogether, our results indicate that agmatine in an animal model of NAFLD—apoE−/− mice fed a Western diet—comprehensively inhibits the DNL pathway in the liver as well as beneficially alters the plasma lipid profile, and may be a promising drug candidate for prevention or treatment of fatty liver and atherosclerosis.